Poteligeo
What Poteligeo is used for
Poteligeo is indicated for the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Poteligeo
- Active substance
- mogamulizumab
- Disease area
- Sezary Syndrome; Mycosis Fungoides
- Medicine group
- Antineoplastic agents
- ATC code
- L01XC25
- Marketing authorisation holder
- Kyowa Kirin Holdings B.V.
- Authorised in the EU since
- 2018
Official information
In the USA
Same active substance: Poteligeo
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Poteligeo used for?
Poteligeo is indicated for the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy.
What is the active substance in Poteligeo?
Poteligeo contains mogamulizumab.
Who makes Poteligeo?
The EU marketing authorisation holder is Kyowa Kirin Holdings B.V..
Is Poteligeo an orphan medicine?
Yes. Poteligeo is designated an orphan medicine in the EU, for a rare disease (Sezary Syndrome; Mycosis Fungoides).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU